For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 31-November 6, 2026
Drug pricing and PBMs Medicare’s second round of negotiated prices starts in two months. On January 1, negotiated prices for…
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Search Posts
Blog
Drug lag — precaution or pipelines?
According to a CNN Money article, a report released yesterday shows that the FDA has been cracking down on new drug approvals. Pharmaceutical companies…
Newsletter
CEI Daily Update
Issues in the News 1. HEALTH A pending bill in Congress would ban the use of genetic testing by insurance companies…
Newsletter
CEI Daily Update
Issues in the News 1. ENVIRONMENT NASA orders a review of climate data after an independent researcher discovers that 1934 – not 1998 as…
Blog
No Excuse for Resistance to DDT
Anti-DDT activists in the environmental movement often suggest we should stop using this chemical to save people from malaria and other diseases because mosquitoes will…
Newsletter
CEI Daily Update
Issues in the News 1. LEGAL Government officials in Nigeria attempt to sue drug maker Pfizer for $2 billion. CEI…
Blog
More on Bad Court Ruling Against Terminally Ill
“Terminally ill patients do not have a constitutional right to be treated with experimental drugs, even if they likely will be dead before the medicine…